Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose,
parallel-group study that will investigate the efficacy and safety of two doses of TNX-102 SL
-a sublingual formulation of cyclobenzaprine. Following successful screening and
randomization, eligible subjects will return regularly to the study clinic for weekly or
biweekly visits for assessments of efficacy and safety.